BioNTech SE (BNTX)

Hello everyone. I'm a doctor and I've been in the stock market for about a year. I did an analysis by Biontech and I think that the market is missing something. I'll be happy if someone gives me feedback and shows me I'm wrong. 1. Biontech has the best vaccine technologically and modernly with Moderna. As a doctor, I must say that the recent price correction of the mRNA vaccine producers Biontech and Moderna in the context of the results of the phase 3 MOVe-OUT study on MERCK's Molnupiravir makes absolutely no sense. Molnupiravir in modern medicine has absolutely no competition for vaccines. It will not lead to their reduced use, nor will it be mentioned in the guidelines as an alternative to vaccination. Even a layman will understand why from the data below. Molnupiravir has been proposed as adjunctive therapy to patients with COVID-19 who have become ill despite vaccination. In these cases, if they have a mild or moderate course of the disease at the beginning of the disease (in severe cases, it has not even been tested), they will reduce the risk of being hospitalized by only 50% within 29 days of infection. In contrast, Biontech was the first to come up with the results of a large study that confirms that after receiving a booster dose of the 3rd dose of Pfizer / Biontech, it should guarantee you with a 95.6% probability that you will not get Covid 19 at all. Imagine that we had two groups of 100 people, one we did not vaccinate and in case of COVID 19 infection they used Molnupiravir and the other group had 3 doses of Pfizer / Biontech. In the first group, due to the huge infectivity of the delta variant, everyone would gradually become infected, economically, each of those infected for at least 2 weeks could not be active and about 7 of them would get to the hospital due to more difficult course / if they did not get Molnupiravir 14 would get in the hospital /. In the fully vaccinated group, only 4 would be infected and none would get in hospital. 2. Pfizer / Biontech increased the prices of one batch from 1.8.2021. Now he sells at least one dose in Europe for about $ 25. They will produce at least 4 billion batches next year, as confirmed by Pfizer CEO Albert Bourla. So the market capitalization of a 71 B company that will earn about 50 B next year is OK? Surely the question is - will they sell them all? I say yes and they would sell even more. Why? MRNA vaccines outperform and defeat other alternatives in terms of efficacy and minimal side effects, so only Comirnaty (Pfizer / BioNTech) and Spikevax (Moderna) vaccines are used for revaccination, at least in Europe and in my country. Other vaccines will not be used for revaccination. Ie. even a person who has been vaccinated with eg Vaxzevria (AstraZeneca) and others will only be revaccinated with the mRNA vaccine. 3. It is almost certain that human society will never get rid of COVID 19, the question is how often and whether we will have to be revaccinated repeatedly. Personally, I'm sure it will be 1 dose every year. Which would earn Biontech at least about 50 B a year just for vaccines a year. However, they also have other preparations, especially from the oncological field in phase II, for mRNA technology, which will potentially generate more money for them in the future ... In the context of the above, is the current stock price OK?